Review
Ledipasvir/Sofosbuvir (Harvoni): For the Treatment of Chronic Hepatitis C Virus (CHC) G1 Infection in Adults [Internet]
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Jul.
- PMID: 27227210
- Bookshelf ID: NBK362643
Item in Clipboard
Review
Ledipasvir/Sofosbuvir (Harvoni): For the Treatment of Chronic Hepatitis C Virus (CHC) G1 Infection in Adults [Internet]
Excerpt
The objective of this report was to perform a systematic review of the beneficial and harmful effects of ledipasvir plus sofosbuvir (LDV/SOF) for the treatment of chronic hepatitis C virus (HCV) G1 infection in adults.
Copyright © CADTH 2015.
Sections
-
Clinical Review Report
- ABBREVIATIONS
- EXECUTIVE SUMMARY
- 1. INTRODUCTION
- 2. OBJECTIVE AND METHODS
- 3. RESULTS
- 4. DISCUSSION
- 5. CONCLUSIONS
- APPENDIX 1 PATIENT INPUT SUMMARY
- APPENDIX 2 LITERATURE SEARCH STRATEGY
- APPENDIX 3 EXCLUDED STUDIES
- APPENDIX 4 DETAILED OUTCOME DATA
- APPENDIX 5 VALIDITY OF OUTCOME MEASURES
- APPENDIX 6 APPRAISAL OF MANUFACTURER-SUBMITTED INDIRECT COMPARISON
- REFERENCES
-
Pharmacoeconomic Review Report
- ABBREVIATIONS
- EXECUTIVE SUMMARY
- 1. SUMMARY OF THE MANUFACTURER’S PHARMACOECONOMIC SUBMISSION
- 2. MANUFACTURER’S BASE CASE
- 3. SUMMARY OF MANUFACTURER’S SENSITIVITY ANALYSES
- 4. LIMITATIONS OF MANUFACTURER’S SUBMISSION
- 5. CADTH COMMON DRUG REVIEW ANALYSES
- 6. ISSUES FOR CONSIDERATION
- 7. PATIENT INPUT
- 8. CONCLUSIONS
- APPENDIX 1 COST COMPARISON
- APPENDIX 2 SUMMARY OF KEY OUTCOMES
- APPENDIX 2 ADDITIONAL INFORMATION
- APPENDIX 3 REVIEWER WORKSHEETS
- REFERENCES
- CDEC Final Recommendation
Similar articles
-
Efficacy and Safety of Ledipasvir/Sofosbuvir with and without Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: a meta-analysis.Int J Infect Dis. 2017 Feb;55:56-71. doi: 10.1016/j.ijid.2016.12.023. Epub 2016 Dec 29. Int J Infect Dis. 2017. PMID: 28040553
-
Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir-experienced, NS5A treatment-naïve patients: Findings from two randomized trials.Liver Int. 2018 Jun;38(6):1010-1021. doi: 10.1111/liv.13616. Epub 2017 Dec 5. Liver Int. 2018. PMID: 29091342 Free PMC article. Clinical Trial.
-
Cost-utility analysis of ledipasvir/sofosbuvir for the treatment of genotype 1 chronic hepatitis C in Japan.Curr Med Res Opin. 2017 Jan;33(1):11-21. doi: 10.1080/03007995.2016.1222513. Epub 2016 Sep 9. Curr Med Res Opin. 2017. PMID: 27609424
-
Fixed-dose combination of sofosbuvir and ledipasvir for the treatment of chronic hepatitis C genotype 1.Expert Opin Pharmacother. 2015 Apr;16(5):739-48. doi: 10.1517/14656566.2015.1013938. Epub 2015 Feb 13. Expert Opin Pharmacother. 2015. PMID: 25676581 Review.
-
An evaluation of ledipasvir + sofosbuvir for the treatment of chronic hepatitis C infection.Expert Opin Pharmacother. 2021 Oct;22(14):1839-1846. doi: 10.1080/14656566.2021.1943359. Epub 2021 Jul 1. Expert Opin Pharmacother. 2021. PMID: 34157923 Free PMC article. Review.
Publication types
LinkOut - more resources
Full Text Sources
